Research Analysts Offer Predictions for MBRX FY2025 Earnings

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Analysts at HC Wainwright boosted their FY2025 EPS estimates for Moleculin Biotech in a report released on Monday, March 24th. HC Wainwright analyst V. Bernardino now expects that the company will post earnings of ($1.65) per share for the year, up from their previous estimate of ($3.31). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($7.98) per share.

A number of other brokerages have also issued reports on MBRX. StockNews.com raised Moleculin Biotech to a “sell” rating in a report on Wednesday. Maxim Group upgraded Moleculin Biotech from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a report on Tuesday.

Moleculin Biotech Trading Down 1.9 %

Shares of NASDAQ:MBRX opened at $1.05 on Thursday. The stock has a fifty day moving average of $1.30 and a 200-day moving average of $1.99. Moleculin Biotech has a one year low of $0.40 and a one year high of $6.23.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.